Fig. 2 | Signal Transduction and Targeted Therapy

Fig. 2

From: Safety and efficacy of trifluridine/tipiracil +/− bevacizumab plus XB2001 (anti-IL-1α antibody): a single-center phase 1 trial

Fig. 2

Pharmacokinetic analysis. a–e Dose-dependent pharmacokinetic measures of XB2001. Area under the curve (a), Cmax (b), half-life (c), clearance (d) and volume of distribution (e) are presented for the doses 250, 500 and 1000 mg. f Evaluation of XB2001 concentration in patient plasma over the first 5 treatment cycles according to the dose given (250, 500 or 1000 mg of XB2001). Measurement of IgG1 (g) and IgG3 (h) anti-drug antibody concentrations in patient plasma at C1D1, C2D1 and C5D1. n.s, not significant, comparison using Wilcoxon matched-pairs test

Back to article page